OncoMatch/Clinical Trials/NCT06641908
Anti-GD2 ADC M3554 in Advanced Solid Tumors
Is NCT06641908 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies M3554 for advanced solid tumor.
Treatment: M3554 — The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype. Study details include: Study Duration per participant: Approximately 4 months
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: IDH1 wild-type
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anthracycline — locally advanced/metastatic
progressed after at least one prior line of anthracycline-containing systemic therapy for the locally advanced/metastatic setting
Must have received: radiation therapy
progressed after ONLY one prior line of therapy (including radiotherapy +/- temozolomide, depending on the O^6-methylguanine-DNA methyltransferase [MGMT] status)
Lab requirements
Blood counts
adequate hematologic function as defined in protocol
Kidney function
adequate renal function as defined in protocol
Liver function
adequate hepatic function as defined in protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana-Farber Cancer Institute · Boston, Massachusetts
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - Memorial Sloan Kettering Cancer Center (CC)- Westc · New York, New York
- The University of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify